The record
Written from the 1 report below. Nothing here is unsourced.
- AstraZeneca shares dropped seven percent after reports emerged of buyout talks with Bristol Myers Squibb valued at around $400 billion.
- Investors expressed doubts about the benefits of a potential merger between the two pharmaceutical companies.
- While a deal could strengthen the combined firm's position in the US market and generate cost savings, shareholders appeared unconvinced that these gains outweighed the risks.
What to watch next
- Whether AstraZeneca or Bristol Myers Squibb confirm or deny the buyout talks
- Investor reaction and share price movement as more deal details emerge
- Any statements on expected US market gains and cost synergies from a potential merger
Coverage1
1 report
English national1
All filed from India
Named United States · AstraZeneca · Bristol Myers Squibb
The 1 report is listed beside the record.
Ask this story
Answers cite the reports above, or say they can't.